ATHENA develops surrogate organ program for toxicity testing Creating surrogate human being organs.
Andrzej Przekwas, CTO and Senior Vice President for Research of CFD Research Corporation , a technology company in Huntsville, AL, can be building a mathematical style of ATHENA to facilitate program design and physiologically-centered pharmacokinetic/pharmacodynamic models to steer drug exposure studies and data extrapolation. ‘This component is exclusive and important when building a ex vivo program mimicking the body,’ stated the DTRA plan manager. LANL and Vanderbilt in collaboration with CFDRC will establish a blood mimic to sustain the four devices. And simply because Iyer puts it ‘a system is only as good as its analytical strength.This method of validating cases based on THIN data offers been successfully found in other studies. Using risk-arranged control sampling, we defined the date of the end of the follow-up period for the controls as the date when the case individual received a analysis. There have been no unmatched case individuals. For the analysis of the nonuse or usage of antiepileptic medicines within each category of illness, another set of settings, matched according to age, sex, clinical practice, and psychiatric or neurologic condition, was chosen. A total of 103 case patients didn’t match any settings. Statistical Analysis We described the features of the many cohorts using regularity tables.